<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021760</url>
  </required_header>
  <id_info>
    <org_study_id>RECOND</org_study_id>
    <nct_id>NCT02021760</nct_id>
  </id_info>
  <brief_title>Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction</brief_title>
  <acronym>RECOND</acronym>
  <official_title>Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction in Stockholm (RECOND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Pernow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Trial objective: To test the hypothesis that remote per-postconditioning in connection&#xD;
           with primary PCI will reduce myocardial infarct size patients with STEMI.&#xD;
&#xD;
        -  Trial Design: Placebo controlled randomized study with parallel groups&#xD;
&#xD;
        -  Primary Endpoint: Myocardial infarct size expressed as a percentage of the myocardium at&#xD;
           risk determined by Cardiac Magnetic Resonance (CMR) day 4-7&#xD;
&#xD;
        -  Efficacy Parameters: Myocardial infarct size expressed as a percentage to the myocardium&#xD;
           at risk determined by CMR at 6 months.&#xD;
&#xD;
        -  Global left ventricular function determined by left ventricular ejection fraction&#xD;
           determined by CMR.&#xD;
&#xD;
        -  Microvascular obstruction determined by CMR day 4-7. Quantified ECV (extracellular&#xD;
           volume) in left ventricular as myocardium at risk day 4-7 and remodelling parameters day&#xD;
           180.&#xD;
&#xD;
        -  Safety Parameters: Major adverse cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above. 3 patients left to include.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance</measure>
    <time_frame>4-7 days following index event</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size expressed as a percentage to the myocardium at risk determined by Cardiac Magnetic Resonance</measure>
    <time_frame>6 months following index event</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Global left ventricular function determined by left ventricular ejection fraction determined by CMR.</measure>
    <time_frame>4-7 days and 6 months following index event</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular obstruction determined by CMR</measure>
    <time_frame>4-7 days following index event</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantified ECV (extracellular volume) in left ventricular as myocardium at risk</measure>
    <time_frame>4-7 days following index event</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarct size by CMR expressed as a percentage to the myocardium at risk determined by Bari or modified Approach Score with coronary angiography.</measure>
    <time_frame>5-7 days following index event</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Remote Ischemic per-postconditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if &gt;180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham procedures include application of the cuff around the thigh but it is not inflated.&#xD;
Otheriwize normal primary PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary Percutaneous Coronary Intervention</intervention_name>
    <description>Primary Percutanous Coronary Intervention is performed in both Groups.</description>
    <arm_group_label>Remote Ischemic per-postconditioning</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient planned for primary PCI.&#xD;
&#xD;
          -  Chest pain indicating myocardial ischemia with a duration &gt;30 minutes and &lt; 6 hours&#xD;
             prior to randomization.&#xD;
&#xD;
          -  ST elevations &gt;0.1 mV (&gt;0.2 mV in V2-V3) in &gt; two contiguous leads in V1-V6.&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous myocardial infarction based on medical history or Q-wave on ECG in other area&#xD;
&#xD;
          -  Left Bundle Branch Block on ECG.&#xD;
&#xD;
          -  Previous CABG&#xD;
&#xD;
          -  Cardiac arrest&#xD;
&#xD;
          -  Any contraindication for CMR.&#xD;
&#xD;
          -  Clinical symptoms of claudication&#xD;
&#xD;
          -  Treatment with glibenclamide or cyclosporine on admission.&#xD;
&#xD;
          -  Any condition that may interfere with the possibility for the patient to comply with&#xD;
             or complete the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pernow, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SÃ¶dersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>John Pernow</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

